FTD Therapeutic Landscape

FTD Therapeutic Landscape

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FTD Therapeutic Landscape</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Agents</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>Citalopram, sertraline, fluoxetine</td>
</tr>
<tr>
<td class="label">Atypical antipsychotics</td>
<td>Risperidone, quetiapine</td>
</tr>
<tr>
<td class="label">Stimulants</td>
<td>Methylphenidate, modafinil</td>
</tr>
<tr>
<td class="label">Anticonvulsants</td>
<td>Valproate, carbamazepine</td>
</tr>
<tr>
<td class="label">NMDA antagonist</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Benzodiazepines</td>
<td>Lorazepam, clonazepam</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LMTM (Leuco-methylthioninium)</td>
<td>TauRx</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate/taurursodiol</td>
<td>Amylyx</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">[GSK-3β](/

FTD Therapeutic Landscape

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">FTD Therapeutic Landscape</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Agents</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>Citalopram, sertraline, fluoxetine</td>
</tr>
<tr>
<td class="label">Atypical antipsychotics</td>
<td>Risperidone, quetiapine</td>
</tr>
<tr>
<td class="label">Stimulants</td>
<td>Methylphenidate, modafinil</td>
</tr>
<tr>
<td class="label">Anticonvulsants</td>
<td>Valproate, carbamazepine</td>
</tr>
<tr>
<td class="label">NMDA antagonist</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Benzodiazepines</td>
<td>Lorazepam, clonazepam</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LMTM (Leuco-methylthioninium)</td>
<td>TauRx</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate/taurursodiol</td>
<td>Amylyx</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">[GSK-3β](/entities/gsk3-beta)</td>
<td>Tideglusib</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB100</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">ASO targeting TDP-43</td>
<td>Ionis/Alnylam</td>
</tr>
<tr>
<td class="label">ION363 (Fischer)</td>
<td>Ionis</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-TARDBP-siRNA</td>
<td>TDP-43</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Progranulin replacement</td>
<td>AAV-GRN</td>
</tr>
<tr>
<td class="label">Progranulin augmentation</td>
<td>AT-GAA</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>ASO-GRN</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>ASO-[C9orf72](/entities/c9orf72)</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>siRNA</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tau ASO</td>
<td>MAPT mRNA</td>
</tr>
<tr>
<td class="label">Tau gene editing</td>
<td>MAPT</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">[TREM2](/proteins/trem2)</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Inhibitor</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-CNTF</td>
<td>Ciliary neurotrophic factor</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>Glial cell line-derived neurotrophic factor</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Active Trials</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>34</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>46</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>12</td>
</tr>
<tr>
<td class="label">Total</td>
<td>~124</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT04345601</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">NCT04735561</td>
<td>BIIB100</td>
</tr>
<tr>
<td class="label">NCT05462106</td>
<td>AL002</td>
</tr>
<tr>
<td class="label">NCT05635007</td>
<td>AAV-GRN</td>
</tr>
<tr>
<td class="label">Company</td>
<td>FTD Programs</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>TDP-43, C9orf72</td>
</tr>
<tr>
<td class="label">Roche/Genentech</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">Eisai</td>
<td>Tau, amyloid</td>
</tr>
<tr>
<td class="label">Pfizer/Prevail</td>
<td>GRN</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>TREM2, tau</td>
</tr>
<tr>
<td class="label">Alector</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Ionis</td>
<td>Genetic ASOs</td>
</tr>
<tr>
<td class="label">TauRx</td>
<td>Tau aggregation</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus Area</td>
</tr>
<tr>
<td class="label">Cerevel</td>
<td>D1/D2 agonists</td>
</tr>
<tr>
<td class="label">AC Immune</td>
<td>Tau vaccines</td>
</tr>
<tr>
<td class="label">Prothelia</td>
<td>Progranulin</td>
</tr>
<tr>
<td class="label">Vigil</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>40% of FTD cases</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>50% of FTD cases</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>~10% of FTD (genetic)</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>~10% of FTD (genetic)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Microglial dysfunction</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Microglial modulation</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">RNA splicing modifiers</td>
<td>TDP-43 function</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[NfL](/biomarkers/neurofilament-light-chain-nfl) (Neurofilament Light)</td>
<td>Axonal damage</td>
</tr>
<tr>
<td class="label">p-tau181/217</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">NGP (Neurogranin)</td>
<td>Synaptic dysfunction</td>
</tr>
<tr>
<td class="label">Progranulin</td>
<td>GRN mutations</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Metabolic changes</td>
</tr>
<tr>
<td class="label">MR volumetry</td>
<td>Atrophy progression</td>
</tr>
</table>

The Frontotemporal Dementia (FTD) therapeutic landscape encompasses the complete spectrum of treatment approaches, from currently available symptomatic therapies to disease-modifying treatments in development. FTD represents a challenging therapeutic area due to its clinical heterogeneity and underlying pathology (tau, TDP-43, or FUS). This page provides a comprehensive map of the therapeutic ecosystem.

Last updated: 2026-03-20

Current Treatment Landscape

FDA-Approved Treatments

No disease-modifying therapies are currently FDA-approved for FTD. This remains a critical unmet need. The only FDA-approved neurodegenerative disease-modifying treatments are [amyloid-targeting antibodies](/therapeutics/alzheimers-disease-treatment) for Alzheimer's disease ([lecanemab](/entities/lecanemab), donanemab).

Off-Label Symptomatic Treatments

Non-Pharmacological Interventions

• Speech and language therapy for PPA variants
• Occupational therapy for functional maintenance
• Behavioral modification strategies
• Caregiver education and support
• Environmental modifications

Disease-Modifying Therapies in Development

Tau-Targeted Approaches

Tau pathology is present in approximately 40% of FTD cases (primarily [MAPT](/proteins/tau) mutations and CBD/PSP overlap).

Anti-Tau Antibodies

Tau Aggregation Inhibitors

Tau Kinase Inhibitors

TDP-43-Targeted Approaches

TDP-43 pathology is present in approximately 50% of FTD cases (most sporadic FTD, GRN mutations, C9orf72).

Antisense Oligonucleucleotides (ASOs)

Gene Therapy

Genetic Subtype-Specific Therapies

GRN (Progranulin) Mutations

C9orf72 Mutations

MAPT Mutations

Neuroinflammation Modulation

Microglial activation is a key contributor to FTD progression.

Neurotrophic Factor Delivery

Clinical Trial Landscape

Trial Statistics

Active Registrational Trials

Trial Design Innovations

• Adaptive trials allowing mid-study modifications
• Platform trials testing multiple therapies simultaneously
• Basket trials enrolling patients by biomarker rather than diagnosis
• Remote/hybrid trials reducing patient burden

Key Companies and Programs

Major Pharmaceutical Companies

Biotechnology Companies

Target Landscape Summary

Well-Validated Targets

Emerging Targets

Biomarkers in Development

Fluid Biomarkers

Imaging Biomarkers

Regulatory Landscape

Breakthrough Therapy Designations

• AL002 (TREM2 agonist): Granted BTD for FTD
• AAV-GRN: Granted Rare Pediatric Disease designation
• BIIB100: Granted Fast Track designation

Regulatory Challenges

Challenges and Opportunities

Key Challenges

Strategic Opportunities

See Also

• [Frontotemporal Dementia (FTD) Treatment](/therapeutics/frontotemporal-dementia-ftd-treatment)
• [FTD Biomarkers](/diagnostics/ftd-biomarkers)
• [FTD Mechanistic Pathway](/mechanisms/frontotemporal-dementia-pathway)
• [Behavioral Variant FTD](/diseases/behavioral-variant-ftd)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Tau-Targeted Therapies](/therapeutics/tau-targeted-therapies)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) &#x1f504;